Table 1 Patient characteristics by quartiles of FIB-4 at baseline

N

991

990

990

991

AKI stage, n (%)

Stage 1

442 (44.601)

432 (43.636)

393 (39.697)

358 (36.125)

Stage 2

327 (32.997)

318 (32.121)

331 (33.434)

354 (35.721)

Stage 3

222 (22.402)

240 (24.242)

266 (26.869)

279 (28.153)

Age

54.217 (18.135)

64.938 (16.388)

68.903 (15.364)

70.277 (14.536)

Gender(male), n (%)

584 (58.930)

585 (59.091)

580 (58.586)

589 (59.435)

Weight (Kg)

85.675 (26.086)

83.439 (24.102)

81.689 (24.089)

80.030 (20.430)

Admission type, n (%)

MICU

517 (52.17)

478 (48.283)

429 (43.333)

386 (38.951)

CCU

152 (15.338)

184 (18.586)

208 (21.01)

205 (20.686)

SICU

144 (14.531)

133 (13.434)

121 (12.222)

115 (11.604)

Others

178 (17.962)

195 (19.697)

232 (23.434)

285 (28.759)

Ethnicity, n (%)

White

652 (65.79)

690 (69.70)

698 (70.51)

670 (67.61)

Black

117 (11.81)

105 (10.61)

87 (8.79)

82 (8.27)

Asian

24 (2.42)

31 (3.13)

27 (2.73)

22 (2.22)

Others

198 (19.98)

164 (16.57)

178 (17.98)

217 (21.90)

ICU intervention

Mechanical ventilation

(first24hours), n (%)

274.138 (71.222)

221.546 (67.182)

187.199 (69.434)

152.168 (65.734)

Vasopressor (first24hours), n (%)

25(19–38)

37 (24–59)

58(36–101)

153(75–318)

Renal replacement therapy, n (%)

24 (17–42)

28 (17–50)

35(19–74)

63 (30–159)

Fluid input

(first 48 h) (ml)

477 (48.133)

479 (48.384)

569 (57.475)

608 (61.352)

266 (26.842)

294 (29.697)

412 (41.616)

501 (50.555)

92 (9.284)

109 (11.01)

106 (10.707)

155 (15.641)

1737(492–3750)

1722(531–3373)

1962 (737–3615)

2084 (856–4059)

Fluid balance

Volume (first 24 h) (ml)

1239 (− 367–3484)

1214 (− 165–3692)

1744(45–4255)

2448 (407–5585)

Positive, n (%)

658 (68.973)

679 (72.311)

717 (75.793)

757 (80.361)

Volume (second 24 h) (ml)

220(− 909–2119)

280 (− 653–1822)

600(− 526–2259)

713 (− 713–2783)

Positive, n (%)

442 (54.907)

478 (58.01)

526 (62.619)

545 (63.892)

Laboratory

Hemoglobin(g/L)

18.484 (5.287)

19.633 (5.046)

20.870 (5.036)

21.491 (5.545)

WBC(10^9/L)

4 (2–6)

4.5 (3–7)

6(4–8)

7(5–10)

PH

5.5 (0–12)

7(3–13)

10 (5–15)

10(5–16)

PLT(10^9/L)

11.431 (2.179)

11.078 (2.082)

10.945 (2.11)

10.693 (2.2)

AST(u/L)

12(8.55–16.4)

11.4 (8.2–15.7)

11.45 (8–16.1)

11.3(8–16.4)

ALT(u/L)

7.350 (0.104)

7.339 (0.095)

7.334 (0.103)

7.328 (0.113)

Co-morbidities, n (%)

CHF

234 (23.613)

332 (33.535)

366 (36.970)

348 (35.116)

AFib

176 (17.76)

264 (26.667)

331 (33.434)

366 (36.932)

Chronic renal disease

140 (14.127)

182 (18.384)

197 (19.899)

187 (18.87)

COPD

107 (10.797)

125 (12.626)

117 (11.818)

112 (11.302)

CAD

172 (17.356)

254 (25.657)

287 (28.99)

353 (35.621)

Stoke

94 (9.485)

88 (8.889)

70 (7.071)

64 (6.458)

Malignancy

126 (12.714)

144 (14.545)

162 (16.364)

148 (14.934)

Sepsis

438 (44.198)

486 (49.091)

513 (51.818)

533 (53.784)

ARDS

52 (5.247)

54 (5.455)

58 (5.859)

59 (5.954)

Outcomes

In-hospital mortality, n (%)

86 (8.678%)

128 (12.929%)

174 (17.576%)

200 (20.182%)

28-day mortality, n (%)

93 (9.384%)

144 (14.545%)

178 (17.980%)

199 (20.081%)

90-day mortality, n (%)

143 (14.430%)

207 (20.909%)

268 (27.071%)

275 (27.750%)